Table 1.
Published details of STRN-ALK-positive NSCLC patients treated with ALK-TKIs.
| Ref | Year | Accompanying Mutations | ALK-TKIs | Treatment | Response | |
|---|---|---|---|---|---|---|
| 1 | Yang, Y. et al. [76] | 2017 | MYC amplification; TP53 (R181C) | Crizotinib | Third line | CR > 6 m |
| 2 | Zhou, C. et al. [75] | 2019 | EGFR (19DEL) | Crizotinib +Gefitinib |
Third line | PR > 6 m |
| 3 | Nakanshi, Y. et al. [64] | 2017 | ABCB1 mRNA overexpression | Alectinib | First line | PD < 3 m |
| 4 | Su, C. et al. [18] | 2020 | GRM8 (E508K); SETD2 (E1553K) |
Alectinib | First line | PR > 19 m |
| 5 | Nagasaka, M. et al. [69] | 2020 | TP53 (L43fs);MYC amplification | Alectinib | First line | PR > 6 m |
| 6 | Zeng, H. et al. [68] | 2020 | PDK1-ALK (P7: A20); TP53 | Alectinib | First line | PR > 7 m |
| 7 | Li, M. et al. [71] | 2021 | MET amplification | Alectinib Crizotinib |
First line Second line |
PD: 3 m PFS > 11 m |